Business Context and Reporting Period
Company: Dow Inc. (DOW) and The Dow Chemical Company (TDCC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Overview: Dow is a leading materials science company operating through three primary segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings. The company operates 91 manufacturing sites in 29 countries and employs approximately 34,600 people. The 2025 fiscal year was characterized by a significant industry downturn, slower global GDP growth, and macroeconomic volatility, leading to substantial restructuring and cost-reduction initiatives.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $39.97 billion | $42.96 billion | -7.0% |
| Net Income (Loss) Available to Common Stockholders | $(2.62) billion | $1.12 billion | Turned to Loss |
| Earnings (Loss) Per Share (Diluted) | $(3.70) | $1.57 | N/A |
| Operating Cash Flow (Continuing Ops) | $1.06 billion | $2.90 billion | -63.4% |
| Free Cash Flow (Non-GAAP) | $(1.42) billion | $(0.04) billion | Worsened |
| Capital Expenditures | $2.48 billion | $2.94 billion | -15.6% |
| Total Debt (Gross) | $18.16 billion | $16.34 billion | +11.1% |
| Cash and Cash Equivalents | $3.82 billion | $2.19 billion | +74.4% |
| Net Debt (Non-GAAP) | $13.96 billion | $13.77 billion | +1.4% |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 7% year-over-year, driven primarily by a 7% decrease in local price across all segments due to industry overcapacity and lower energy/feedstock costs. Volume was flat overall, with gains in the U.S. & Canada and Asia Pacific offset by declines in EMEAI and Latin America.
- Significant Impairments and Charges: The company recorded $1.86 billion in restructuring, goodwill impairment, and asset-related charges in 2025, compared to $103 million in 2024. Key components included:
- Goodwill Impairment: $690 million charge related to the Polyurethanes & Construction Chemicals reporting unit.
- Asset Impairment: $303 million charge for assets in Latin America (chlor-alkali, propylene oxide, brine).
- Restructuring: $862 million in charges for the 2025 Restructuring Program, including severance ($389 million) and asset write-downs ($349 million).
- Dividend Reduction: In July 2025, the Board reduced the quarterly dividend by 50% to $0.35 per share in response to the industry downturn.
- Joint Venture Losses: Equity in losses of nonconsolidated affiliates increased to $240 million in 2025 from $6 million in 2024, driven by margin compression at principal joint ventures.
Guidance, Outlook, and Management Commentary
- Strategic Initiatives:
- Transform to Outperform: Announced in January 2026, this initiative aims to improve near-term Operating EBITDA by $2 billion through operating model simplification and cost reduction. It involves a workforce reduction of approximately 4,500 roles with expected one-time costs of $1.1 billion to $1.5 billion.
- Asset Rationalization: Plans to shut down an ethylene cracker in Böhlen, Germany (by end of 2027), chlor-alkali assets in Schkopau, Germany (by end of 2027), and a siloxanes plant in Barry, UK (by mid-2026).
- Capital Allocation:
- Capital Expenditures: 2026 CapEx is expected to be approximately $2.5 billion. The Fort Saskatchewan Path2Zero project (net-zero ethylene complex) has been delayed, with startup now expected in 2029-2030.
- Share Repurchases: No shares were repurchased in 2025. Approximately $931 million remains available under the current authorization.
- Outlook by Segment:
- Packaging & Specialty Plastics: Volume growth expected from new polyethylene capacity on the U.S. Gulf Coast.
- Industrial Intermediates & Infrastructure: Improved volume growth expected from alkoxylation capacity expansions.
- Performance Materials & Coatings: Focus on performance silicones for AI/data center applications; coatings market expected to improve in H2 2025 due to rate cuts.
- Risks: Management highlights risks related to climate change commitments, geopolitical conflicts (Russia-Ukraine, Middle East), trade policy uncertainty (tariffs), and the cyclical nature of the chemical industry.
Investor Verification Checklist
- Impairment Validity: Verify the assumptions used in the $690 million goodwill impairment for the Polyurethanes & Construction Chemicals unit, specifically regarding future revenue growth and discount rates.
- Restructuring Execution: Monitor the execution of the "Transform to Outperform" program and the associated $1.1-$1.5 billion in one-time costs to ensure they align with projected EBITDA improvements.
- Joint Venture Exposure: Assess the financial health of major joint ventures (Sadara, EQUATE, Map Ta Phut) given the $240 million equity loss and the potential for further margin compression.
- Liquidity Position: Confirm the company's ability to service its $18.16 billion debt load while maintaining liquidity, especially given the negative free cash flow and reduced dividend.
- Path2Zero Project: Evaluate the impact of the two-year delay on the Fort Saskatchewan project on the company's long-term decarbonization goals and competitive positioning.
- Legal Contingencies: Review the status of the Union Carbide asbestos liability ($708 million accrued) and the ongoing litigation with Nova Chemicals Corporation regarding the ethylene asset judgment.